[1] FLORCZAK E, PREJBISZ A, SZWENCH-PIETRASZ E, et al. Clinical characteristics of patients with resistant hypertension: the RESIST-POL study. J Hum Hypertens,2013,27(11): 678–685. doi: 10.1038/jhh.2013.32
[2] PIMENTA E, CALHOUN D A, OPARIL S. Sleep apnea, aldosterone, and resistant hypertension. Prog Cardiovasc Dis,2009,51(5): 371–380. doi: 10.1016/j.pcad.2008.02.004
[3] PREJBISZ A, KOLODZIEJCZYK-KRUK S, LENDERS J W M, et al. Primary aldosteronism and obstructive sleep apnea: is this a bidirectional relationship? Horm Metab Res,2017,49(12): 969–976. doi: 10.1055/s-0043-122887
[4] 张福春, 严治涛, 杨晶晶, 等. 原发性醛固酮增多症与睡眠呼吸暂停关系的研究现状. 现代生物医学进展,2010,10(4): 794–796.
[5] 中华医学会内分泌学分会肾上腺学组. 原发性醛固酮增多症诊断治疗的专家共识. 中华内分泌代谢杂志,2016,32(3): 188–195. doi: 10.3760/cma.j.issn.1000-6699.2016.03.003
[6] FUNDER J W, CAREY R M, MANTERO F, et al. The management of primary aldosteronism: case detection, diagnosis, andtreatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab,2016,101(5): 1889–1916. doi: 10.1210/jc.2015-4061
[7] 中华医学会呼吸病学分会睡眠呼吸障碍学组. 阻塞性睡眠呼吸暂停低通气综合征诊治指南(2011年修订版). 中华结核和呼吸杂志,2012,35(1): 9–12. doi: 10.3760/cma.j.issn.1001-0939.2012.01.007
[8] FARDELLA C E, MOSSO L, GÓMEZ-SÁNCHEZ C,et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab,2000,85(5): 1863–1867.
[9] MULATERO P, STOWASSER M, LOH K C, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab,2004,89(3): 1045–1050. doi: 10.1210/jc.2003-031337
[10] STOWASSER M, GORDON R D, GUNASEKERA T G, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens,2003,21(11): 2149–2157. doi: 10.1097/00004872-200311000-00025
[11] PEDROSA R P, DRAGER L F, GONZAGA C C, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension,2011,58(5): 811–817. doi: 10.1161/HYPERTENSIONAHA.111.179788
[12] CALHOUN D A, NISHIZAKA M K, ZAMAN M A, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension,2002,40(6): 892–896. doi: 10.1161/01.HYP.0000040261.30455.B6
[13] PIADITIS G, MARKOU A, PAPANASTASIOU L, et al. Progress in primary aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension. Eur J Endocrinol,2015,172(5): 191–203. doi: 10.1530/EJE-14-0537
[14] LOH K C, KOAY E S, KHAW M C, et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab,2000,85(5): 2854–2859.
[15] SANG X, JIANG Y, WANG W, et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J Hypertens,2013,31(7): 1465–1471. doi: 10.1097/HJH.0b013e328360ddf6
[16] OHNO Y, SONE M, INAGAKI N, et al. Obesity as a key factor underlying idiopathic hyperaldosteronism. J Clin Endocrinol Metab,2018,103(12): 4456–4464. doi: 10.1210/jc.2018-00866
[17] 李南方, 史超, 李娟, 等. 阻塞性睡眠呼吸暂停低通气综合征降低原发性醛固酮增多症患者的醛固酮肾素活性比值. 中华高血压杂志,2014,22(3): 242–245.
[18] LI M, GE Q, SHENG C S, et al. Clinical characteristics of snoring patients with primary aldosteronism and obstructive sleep apnea-hypopnea syndrome. J Hum Hypertens,2019,33(9): 693–700. doi: 10.1038/s41371-019-0208-9